Allergy Therapeutics has announced top-line results from its PQBirch204 Phase II study. Primary endpoint has been met and the results have proved the dose-response relationship. Not only does this pave the way towards the Phase III programme on track (expected to commence early 2017), it also potentially acts as a validating/de-risking reference for the company’s wider Pollinex Quattro platform. On this point, we remind investors we will be looking towards results from the US GrassMATAM
